B. West

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

L. Petrucelli, T. Dawson, V. Dawson, 2016 .

Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

N. Socci, B. Taylor, C. Kandoth, 2021, Clinical Cancer Research.

Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit.

I. Puzanov, D. V. Von Hoff, K. Nolop, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors

L. Coussens, H. Rugo, N. Sharma, 2019, Therapeutic advances in medical oncology.